Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce
  
BioMarin's Brineura is not cost-effective, according to England's HTA body NICE.

More from United Kingdom

More from Market Access